Cite
HARVARD Citation
Usmani, S. et al. (2020). Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and SIRIUS trials. Lancet. 7 (6), pp. e447-e455. [Online].